Page last updated: 2024-11-13
psychollatine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
psychollatine: from Psychotria umbellata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 46878353 |
CHEMBL ID | 606760 |
MeSH ID | M0483543 |
Synonyms (2)
Synonym |
---|
CHEMBL606760 |
psychollatine |
Research Excerpts
Overview
Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell.
Excerpt | Reference | Relevance |
---|---|---|
"Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell. " | ( Antioxidant and antimutagenic properties of the monoterpene indole alkaloid psychollatine and the crude foliar extract of Psychotria umbellata Vell. do Nascimento, NC; e Silva, AC; Fett-Neto, AG; Fragoso, V; Moura, DJ; Richter, MF; Saffi, J, 2008) | 2.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (54)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID380146 | Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 50 mg/kg, ip administered 30 mins prior to NMDA challenge | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377507 | Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378495 | Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 100 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377501 | Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378494 | Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377481 | Effect on locomotory activity in CF1 mouse assessed as reduction in spontaneous activity at 100 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380148 | Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 100 mg/kg, ip administered 30 mins prior to NMDA challenge | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377491 | Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 3 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378498 | Anxiolytic activity against CF1 mouse assessed as reduction in number in head dips at 200 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380150 | Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 7.5 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377492 | Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 7.5 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380155 | Decrease in spontaneous locomotor activity in mouse at 100 mg/kg | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377493 | Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 10 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378499 | Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380159 | Protective effect against amphetamine-induced lethality in mouse at 100 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID380151 | Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 10 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID378506 | Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 15 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378500 | Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377477 | Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 100 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380147 | Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 75 mg/kg, ip administered 30 mins prior to NMDA challenge | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID378505 | Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 15 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380157 | Protective effect against amphetamine-induced lethality in mouse at 10 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377494 | Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 30 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378509 | Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 3 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377478 | Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 2 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380154 | Decrease in spontaneous locomotor activity in mouse at 10 mg/kg | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID380161 | Inhibition of apomorphine-induced climbing behavior in mouse at 10 mg/kg, ip administered 30 mins prior to apomorphine challenge | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377466 | Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377499 | Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 0.85 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377495 | Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 100 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377484 | Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions for 60 mins | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378497 | Anxiolytic activity against CF1 mouse assessed as reduction in number in crossings at 200 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377467 | Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377479 | Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 3 to 30 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377486 | Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 7.5 mg/kg during final 4 mins of the 6 mins session by forced swimming test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380153 | Decrease in spontaneous locomotor activity in mouse at 7.5 mg/kg | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377480 | Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 0.75 and 0.85 mg/kg | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377487 | Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 10 mg/kg during final 4 mins of the 6 mins session by forced swimming test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378501 | Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377476 | Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg in presence of ritanserin for 5 mins | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380152 | Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 100 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377471 | Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg for 5 mins | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380158 | Protective effect against amphetamine-induced lethality in mouse at 30 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
AID377498 | Effect on short term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377506 | Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 7.5 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378508 | Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 30 mg/kg during final 4 mins of the 6 mins session by forced swimming test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377468 | Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377485 | Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 3 mg/kg during final 4 mins of the 6 mins session by forced swimming test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377472 | Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg for 5 mins | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377475 | Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg in presence of ritanserin for 5 mins | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID378507 | Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 15 mg/kg after 30 mins by hole-board assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377502 | Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 10 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID377503 | Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 30 mg/kg by by passive avoidance test | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator. |
AID380156 | Protective effect against amphetamine-induced lethality in mouse at 3 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs | 2006 | Journal of natural products, Mar, Volume: 69, Issue:3 | Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |